circomax myco
zoetis belgium - inactivated mycoplasma hyopneumoniae, strain p-5722-3, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2a open reading frame 2 (orf2) protein, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2b orf2 protein - immunologiques pour les suidés - les porcs (pour l'engraissement) - active immunisation of pigs against porcine circovirus type 2 to reduce viral load in blood and lymphoid tissues, fecal shedding and the lesions in lymphoid tissues associated with pcv2 infection. protection was demonstrated against porcine circovirus types 2a, 2b and 2d. active immunisation of pigs against mycoplasma hyopneumoniae to reduce the lung lesions associated with mycoplasma hyopneumoniae infection. onset of immunity (both vaccination schedules): 3 weeks after (the last) vaccination. duration of immunity (both vaccination schedules): 23 weeks after (the last) vaccination. in addition, vaccination has been shown to reduce body weight gain losses under field conditions.
parvovax
ceva sante animale - parvovirus porcin - emulsion injectable - porc reproducteur
porcilis parvo
intervet - parvovirus porcin - suspension injectable - porc reproducteur
porcilis pcv id
intervet international b.v. - antigène de la sous-unité orf2 du circovirus porcin de type 2 - immunologicals for suidae, inactivated viral vaccines - les cochons - for the active immunisation of pigs to reduce viraemia, virus load in lungs and lymphoid tissues and virus shedding caused by pcv2 infection. to reduce loss of daily weight gain and mortality associated with pcv2 infection.
progressis émuls. inj. i.m. flac.
ceva santé animale sa-nv - virus du syndrome dysgénésique et respiratoire porcin, inactivé - emulsion injectable - porcine reproductive and respiratory syndrome (prrs) virus
orgasuline 30/70 100 u.i./ml, suspension injectable en cartouche
organon s.a - insuline humaine hémisynthétique isophane biphasique - suspension - 100 ui - composition pour 1 ml de suspension injectable > insuline humaine hémisynthétique isophane biphasique : 100 ui - insulines et analogues d'action intermediaire et a debut d'action rapide
orgasuline nph 40 ui/ml, suspension injectable en flacon
organon s.a - insuline humaine hémisynthétique isophane (suspension d') - suspension - 40 ui - composition pour 1 ml de suspension injectable > insuline humaine hémisynthétique isophane (suspension d') : 40 ui - insulines et analogues d'action intermediaire.
orgasuline 30/70 40 ui/ml, suspension injectable en flacon
organon s.a - insuline humaine hémisynthétique isophane biphasique - suspension - 40 ui - composition pour 1 ml de suspension injectable > insuline humaine hémisynthétique isophane biphasique : 40 ui - insulines et analogues d'action intermediaire et a debut d'action rapide
orgasuline rapide 100 ui/ml, solution injectable en flacon
organon s.a - insuline humaine hémisynthétique - solution - 100 ui - composition pour 1 ml de solution injectable > insuline humaine hémisynthétique : 100 ui - insulines et analogues d'action rapide
orgasuline nph 100 ui/ml, suspension injectable en flacon
organon s.a - insuline humaine hémisynthétique isophane (suspension d') - suspension - 100 ui - composition pour 1 ml de suspension injectable > insuline humaine hémisynthétique isophane (suspension d') : 100 ui - insulines et analogues d'action intermediaire.